Date: June 3, 2021  Administrative Circular: 2021:22

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products
COVID-19 Vaccines

**COVID-19 mRNA Vaccine BNT162b2 (Pfizer)**
The product page has been revised as follows:

- **Doses and Schedules:**
  - Footnote E has been added indicating that mRNA vaccine can be offered as a second dose to individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, unless contraindicated.

Please remove page numbers: 1-5 dated May 28, 2021
Please add new page numbers: 1-5 dated June 3, 2021

**COVID-19 mRNA Vaccine mRNA-1273 (Moderna)**
The product page has been revised as follows:

- **Doses and Schedules:**
  - Footnote F has been added indicating that mRNA vaccine can be offered as a second dose to individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, unless contraindicated.

Please remove page numbers: 1-4 dated May 28, 2021
Please add new page numbers: 1-4 dated Jun 3, 2021
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)

The product page has been revised as follows:

- **Indications:**
  - Indications have been revised to indicate that the vaccines may be given to individuals 18 years of age and older for dose 2. This age indication has been revised from 30 years as some individuals between 18-30 years of age received a ChAdOx1-S vaccine as dose 1. Further information in Footnote A indicates that these vaccines are no longer being offered as a first dose, unless there is a contraindication to an mRNA vaccine or as advised by the Medical Health Officer or an allergist.

- **Doses and Schedules:**
  - Footnote D has been revised to indicate that those who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated.

- **Adverse Events:**
  - The statement indicating that most cases of Thrombosis with Thrombocytopenia Syndrome (TTS) have occurred in women under 55 years of age has been removed.

Please remove page numbers: 1-4 dated May 28, 2021
Please add new page numbers: 1-4 dated June 3, 2021

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

The product page has been revised as follows:

- **Adverse Events:**
  - The statement indicating that most cases of Thrombosis with Thrombocytopenia Syndrome (TTS) have occurred in women under 55 years of age has been removed.

Please remove page numbers: 1-4 dated May 28, 2021
Please add new page numbers: 1-4 dated June 3, 2021

Please note the additional resources that have been posted to the BCCDC website:

- BCCDC Health Care Professional Q&A - Second dose considerations for those who received AstraZeneca or COVISHIELD for first dose COVID-19 immunization
  
  This is a new resource developed to provide information on the June 1st NACI second
dose considerations for individuals who have received AstraZeneca/COVISHIELD vaccine as a first dose. This resource can be found on the COVID-19 Vaccination Toolkit for Health Professionals webpage.

- **COVID-19 Vaccination - Second dose vaccine choice for people who received AstraZeneca/COVISHIELD**
  
  This is a new public-facing resource to support AstraZeneca/COVISHIELD first dose recipients to make an informed decision regarding their second dose of COVID-19 vaccine. This resource will be translated into several different languages and can be found on the Vaccine registration and eligibility webpage.

- **BCCDC COVID-19 Guidance Document on the Management of Inadvertent Vaccine Errors**
  
  This is a new resource, adapted from the Public Health Agency of Canada, to assist healthcare providers to manage COVID-19 vaccines that are administered in a matter that differs from the recommendations within the BC Immunization Manual. This resource can be found on the COVID-19 Vaccination Toolkit for Health Professionals webpage.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

[Signature]

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc: Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division